Fig. 3.

Length of stay in the initial facility where they were admitted (expressed as days, based on day of admission and discharge), for patients with a principal non-VPD diagnosis without secondary VPD compared to a principal non-VPD with secondary VPD. The data are drawn from all claims registered with the MarketScan Commercial Claims and Encounters (Commercial), Medicare Supplemental (Medicare) and Multistate Medicaid (Medicaid) databases from July 1, 2016 to June 30, 2019. Data from Commercial/Medicare were pooled (n = 1,964,984) according to standard practice and presented alongside Medicaid claims (n = 1,162,784). VPD vaccine-preventable diseases, A00-B99 Certain infections and parasitic diseases, C00-D49 Neoplasma, D50–D89 diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, E00–E89 endocrine, nutritional and metabolic diseases, F01–F99 mental, behavioural and neurodevelopment disorders, G00–G99 diseases of the nervous system, H00–H59 diseases of the eye and adnexa, H60–H95 diseases of the ear and mastoid process, I00–J99 diseases of the circulatory system, J00–J99 diseases of the respiratory system, K00–K95 diseases of the digestive system, L00–L99 diseases of the skin and subcutaneous tissue, M00–M99 diseases of the musculoskeletal system and connective tissue, N00–N99 diseases of the genitourinary system, O00–O94 pregnancy, childbirth and puerperium, Q00–Q99 congenital malformation, deformations and chromosomal abnormalities, R00–R99 symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, S00–T88 injury, poisoning and certain other consequences of external causes, Z00–Z99 factors influencing health status and contact with health services